Emma Bjørk1, Wade Thompson2,3,4, Jesper Ryg4,5,6,7, Ove Gaardboe8, Trine Lembrecht Jørgensen7,9,10, Carina Lundby11,2,3,4. 1. Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense C, Denmark. embjorkol@gmail.com. 2. Research Unit of General Practice, Department of Public Health, University of Southern Denmark, Odense C, Denmark. 3. Hospital Pharmacy Funen, Odense University Hospital, Odense C, Denmark. 4. Odense Deprescribing Initiative (ODIN), Odense C, Denmark. 5. Department of Geriatric Medicine, Odense University Hospital, Odense C, Denmark. 6. Geriatric Research Unit, Department of Clinical Research, University of Southern Denmark, Odense C, Denmark. 7. Academy of Geriatric Cancer Research (AgeCare), Odense University Hospital, Odense C, Denmark. 8. Danish Society for Patient Safety, Frederiksberg, Denmark. 9. Department of Oncology, Odense University Hospital, Odense C, Denmark. 10. Institute of Clinical Research, University of Southern Denmark, Odense C, Denmark. 11. Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense C, Denmark.
Abstract
BACKGROUND: Discussing life expectancy helps inform decisions related to preventive medication, screening, and personal care planning. Our aim was to systematically review the literature on patient preferences for discussing life expectancy and to identify predictors for these preferences. METHODS: We searched PubMed, Cochrane Library, Embase, MEDLINE, PsycInfo, and gray literature from inception until 17 February 2021. Two authors screened titles/abstracts and full texts, and extracted data and one author assessed quality. The outcome of interest was the proportion of patients willing to discuss life expectancy. We reported descriptive statistics, performed a narrative synthesis, and explored sub-groups of patients according to patient characteristics. RESULTS: A total of 41 studies with an accumulated population of 27,570 participants were included, comprising quantitative survey/questionnaire studies (n=27) and qualitative interview studies (n=14). Willingness to discuss life expectancy ranged from 19 to 100% (median 61%, interquartile range (IQR) 50-73) across studies, with the majority (77%) reporting more than half of subjects willing to discuss. There was considerable heterogeneity in willingness to discuss life expectancy, even between studies from patients with similar ages, diseases, and cultural profiles. The highest variability in willingness to discuss was found among patients with cancer (range 19-100%, median 61%, IQR 51-81) and patients aged 50-64 years (range 19-97%, median 61%, IQR 45-87). This made it impossible to determine predictors for willingness to discuss life expectancy. DISCUSSION: Most patients are willing to discuss life expectancy; however, a substantial proportion is not. Heterogeneity and variability in preferences make it challenging to identify clear predictors of willingness to discuss. Variability in preferences may to some extent be influenced by age, disease, and cultural differences. These findings highlight the individual and complex nature in which patients approach this topic and stress the importance of clinicians considering eliciting patient's individual preferences when initiating discussions about life expectancy.
BACKGROUND: Discussing life expectancy helps inform decisions related to preventive medication, screening, and personal care planning. Our aim was to systematically review the literature on patient preferences for discussing life expectancy and to identify predictors for these preferences. METHODS: We searched PubMed, Cochrane Library, Embase, MEDLINE, PsycInfo, and gray literature from inception until 17 February 2021. Two authors screened titles/abstracts and full texts, and extracted data and one author assessed quality. The outcome of interest was the proportion of patients willing to discuss life expectancy. We reported descriptive statistics, performed a narrative synthesis, and explored sub-groups of patients according to patient characteristics. RESULTS: A total of 41 studies with an accumulated population of 27,570 participants were included, comprising quantitative survey/questionnaire studies (n=27) and qualitative interview studies (n=14). Willingness to discuss life expectancy ranged from 19 to 100% (median 61%, interquartile range (IQR) 50-73) across studies, with the majority (77%) reporting more than half of subjects willing to discuss. There was considerable heterogeneity in willingness to discuss life expectancy, even between studies from patients with similar ages, diseases, and cultural profiles. The highest variability in willingness to discuss was found among patients with cancer (range 19-100%, median 61%, IQR 51-81) and patients aged 50-64 years (range 19-97%, median 61%, IQR 45-87). This made it impossible to determine predictors for willingness to discuss life expectancy. DISCUSSION: Most patients are willing to discuss life expectancy; however, a substantial proportion is not. Heterogeneity and variability in preferences make it challenging to identify clear predictors of willingness to discuss. Variability in preferences may to some extent be influenced by age, disease, and cultural differences. These findings highlight the individual and complex nature in which patients approach this topic and stress the importance of clinicians considering eliciting patient's individual preferences when initiating discussions about life expectancy.
Authors: Megan Winner; Ana Wilson; Sean Ronnekleiv-Kelly; Thomas J Smith; Timothy M Pawlik Journal: Ann Surg Oncol Date: 2016-09-08 Impact factor: 5.344
Authors: Nancy L Schoenborn; Ellen M Janssen; Cynthia Boyd; John F P Bridges; Antonio C Wolff; Qian-Li Xue; Craig E Pollack Journal: Ann Fam Med Date: 2018-11 Impact factor: 5.166
Authors: Cyrus Ahalt; Louise C Walter; Lindsey Yourman; Catherine Eng; Eliseo J Pérez-Stable; Alexander K Smith Journal: J Gen Intern Med Date: 2011-11-30 Impact factor: 5.128
Authors: Lisa Jane Mackenzie; Mariko Leanne Carey; Eiji Suzuki; Robert William Sanson-Fisher; Hiromi Asada; Masakazu Ogura; Catherine D'Este; Michio Yoshimura; Masakazu Toi Journal: PLoS One Date: 2018-06-08 Impact factor: 3.240
Authors: Shivani K Jindal; Maria Karamourtopoulos; Alicia R Jacobson; Adlin Pinheiro; Alexander K Smith; Mary Beth Hamel; Mara A Schonberg Journal: J Am Geriatr Soc Date: 2022-02-28 Impact factor: 7.538